By Laura Dyrda
The bone morphogenetic protein market shows sluggish growth in some areas, according to a Research and Markets report.
Here are eight key trends:
1. The rhBMP-2 segment had the largest share of the market in terms of revenue in 2013. It has been widely accepted by physicians due to effectiveness in treating spinal fusions.
2. The rhBMP-7 is expected to completely diminish from the market after the OP-1/Opgenra withdrawal from the market in August 2014.
3. Spinal fusions account for the largest share of the BMP market, followed by trauma.
